Adverse event development in clinical oncology trials reply

被引：1
|
作者：
Thanarajasingam, Gita [1 ]
Sloan, Jeff A. [2 ]
Grothey, Axel [3 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA
[3] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 07期
关键词：
D O I：
10.1016/S1470-2045(16)30245-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E264 / E265
页数：3
相关论文
共 50 条
  • [1] Adverse event development in clinical oncology trials
    Schmoor, Claudia
    Bender, Ralf
    Beyersmann, Jan
    Kieser, Meinhard
    Schumacher, Martin
    [J]. LANCET ONCOLOGY, 2016, 17 (07): : E263 - E264
  • [2] Development and validation of an adverse event causality assessment tool for use in oncology clinical trials
    Coombes, Megan
    Levine, Mitch
    Mukherjee, Som
    Kowaleski, Brenda
    Cosby, Jarold
    Arnold, Andrew
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S180 - S181
  • [3] Adverse event reporting in oncology clinical trials - lost in translation?
    Sivendran, Shanthi
    Galsky, Matthew D.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 893 - 896
  • [4] High grade adverse event reporting and enrolment in gynecologic oncology clinical trials
    Madariaga, Ainhoa
    Cole, Heather
    Pittman, Tyler
    Grant, Robert C.
    Dhani, Neesha C.
    Liu, Amy
    Bowering, Valerie
    Sellman, Susanna
    Oza, Amit M.
    Lheureux, Stephanie
    [J]. GYNECOLOGIC ONCOLOGY, 2024, 185 : 1 - 7
  • [5] ELICITING THE CHILD'S VOICE IN ADVERSE EVENT REPORTING IN ONCOLOGY CLINICAL TRIALS.
    Hinds, Pamela
    Reeve, Bryce
    Jaobs, Shana
    Baker, Justin
    Mack, Jenny
    Withycom, Janice
    [J]. ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [6] Adherence to CONSORT adverse event reporting guidelines in medical oncology clinical trials, a systematic review
    Peron, J.
    Maillet, D.
    Gan, H. K.
    Chen, E. X.
    You, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S192 - S192
  • [7] Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Children's Oncology Group Report
    Miller, Tamara P.
    Marx, Melissa Z.
    Henchen, Christopher
    DeGroote, Nicholas P.
    Jones, Sally
    Weiland, Jenny
    Fisher, Beth
    Esbenshade, Adam J.
    Aplenc, Richard
    Dvorak, Christopher C.
    Fisher, Brian T.
    [J]. JOURNAL OF PATIENT SAFETY, 2022, 18 (03) : E672 - E679
  • [8] Clinical Trials in Oncology and Defining Benefit Reply
    Goldberg, Richard M.
    [J]. ONCOLOGIST, 2018, 23 (01): : 136 - 136
  • [9] Improving attribution of adverse events in oncology clinical trials
    George, Goldy C.
    Barata, Pedro C.
    Campbell, Alicyn
    Chen, Alice
    Cortes, Jorge E.
    Hyman, David M.
    Jones, Lee
    Karagiannis, Thomas
    Klaar, Sigrid
    Le-Rademacher, Jennifer G.
    LoRusso, Patricia
    Mandrekar, Sumithra J.
    Merino, Diana M.
    Minasian, Lori M.
    Mitchell, Sandra A.
    Montez, Sandra
    O'Connor, Daniel J.
    Pettit, Syril
    Silk, Elaine
    Sloan, Jeff A.
    Stewart, Mark
    Takimoto, Chris H.
    Wong, Gilbert Y.
    Yap, Timothy A.
    Cleeland, Charles S.
    Hong, David S.
    [J]. CANCER TREATMENT REVIEWS, 2019, 76 : 33 - 40
  • [10] Adverse event reporting in clinical trials: room for improvement
    Liauw, WS
    Day, RO
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2003, 179 (08) : 426 - 428
12345